glp 1 for cardiovascular disease The conversation around GLP-1 medications is growing, and it goes beyond the number on the scale. According to the American Heart Association, evidence suggests GLP-1s may support heart health and help reduce Glucagon-like peptide 1 receptor agonists:

in the PVT group, 15.9% of the patients died, whereas in the non-PVT group, only 1.7% of the patients died

SGLT-2 inhibitors: the gap seems to be leveling off

The medication mimics your natural GLP-1 peptide hormone, making you feel satisfied after a meal and have fewer cravings

A recent randomized clinical trial from Denmark evaluated weight loss maintenance after one of four 52-week regimens (placebo, once daily liraglutide 3.0 mg alone, supervised exercise alone, or liraglutide plus supervised exercise) in 109 adults with obesity without serious chronic illnesses, including diabetes

The review also emphasized that the renal and hepatic benefits of GLP-1 medicines appear mechanistically linked to both systemic metabolic improvements and local anti-inflammatory signaling